tbuckley/cabot-search huggingface dataset:
Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC).
Authors: V. J. Seery, B. M. McGree, M. Lee, D. F. McDermott, D. C. Cho
Journal: Journal of Clinical Oncology (2010)

9051 Background: Multiple new therapies have been approved for patients (pts) with advanced RCC. As these agents enter widespread use, their perceived toxicities may differ from those reported in the literature and could limit treatment duration and clinical outcomes. Patient reporting of toxicities may more accurately identify side effects most relevant to pts. Methods: In an effort to collect patient-reported side effects from RCC pts treated with novel therapies, an on-line survey was developed. RCC pts were recruited through the Kidney Cancer Association. Results: 177 pts completed the survey and 146 (64%M/36%F) received medication for RCC. Most common geographical regions were Midwest (20.8%); Northeast (17.4%); South/Southeast (16.7%); West (11.8%); and outside the U.S. (9.7%). 68 pts (47.2%) were treated at teaching hospitals; 55 pts (38.2%) in private oncology offices; and 21 pts (14.6%) at community hospitals. First-line treatments included sunitinib (Su) (52.1%, n = 73); sorafenib (So) (15.7%, n = 22); high dose IL-2 (14.3%, n = 20); clinical trial (12.9%, n = 18); bevacizumab (Bev) (5%, n = 7); interferon (4.3%, n = 6) and temsirolimus (Tem) (3.6%, n = 5). The most common side effects reported for Su were fatigue (92.9%, n = 65), altered taste (90%, n = 63) and diarrhea (83.8%, n = 57); So: hand foot syndrome (95.2%, n = 20) and fatigue (95%, n = 19); Bev: fatigue and altered taste (83.3%, n = 5); Tem: fatigue, altered taste and rash (100%, n = 4). Pts reported that the most difficult side effects from Su were diarrhea and fatigue (25%, n = 18); So: hand foot syndrome (72.7%, n = 16); Bev: fatigue (42.9%, n = 3); Tem: rash (60%, n = 3). Side effects necessitated changing the schedule, dose, or stopping Rx in 82% (n = 18) of So pts and in 40% (n = 28) of Su pts. QOL was affected very much/extremely for 56.6% of pts (n = 73). Conclusions: These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Wyeth
Euthanasia and Physician-Assisted Suicide—In Reply
Authors: Ezekiel J. Emanuel, Bregje D. Onwuteaka-Philipsen, Joachim Cohen
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.
Authors: Cristina Rodriguez, Tao Jin, Rony Abou Jawde, Wael Saber, Rachid Baz, Eric His, Matt Kalaycio, Ronald Sobecks, Mikkael Sekeres, Anjali Advani
Journal: Blood (2006)
Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.
Authors: Shernan G. Holtan, Luis F. Porrata, David J. Inwards, Stephen A. Ansell, Douglas J. Padley, Ivana N. Micallef, Mark R. Litzow, Patrick B. Johnston, Suzanne R. Hayman, Shaji K. Kumar, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Dennis A. Gastineau, Ayalew Teferi, Michelle Elliot, William J. Hogan, Svetomir N. Markovic
Journal: Blood (2005)
Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction
Authors: Mary A M Cleaton, Claire L Dent, Mark Howard, Jennifer A Corish, Isabelle Gutteridge, Ulla Sovio, Francesca Gaccioli, Nozomi Takahashi, Steven R Bauer, D Steven Charnock-Jones, Theresa L Powell, Gordon C S Smith, Anne C Ferguson-Smith, Marika Charalambous
Journal: Nature Genetics (2016)
Home care services should give patients more responsibility for medicines, NICE says
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Home care services should give patients more responsibility for managing their own medicines, aided by family or carers if required, the National Institute for Health and Care Excellence has said in draft guidance.1

The homecare services that received the highest rating from the Care Quality Commission in a new report were rated as outstanding mainly because staff took the time to have meaningful discussions with patients.2

NICE says that home care staff should discuss medicinal …
Medical director of Cornwall trust is first to be struck off for management failings
Authors: Clare Dyer
Journal: BMJ (2016)

A former medical director at Royal Cornwall Hospitals NHS Trust who “naively” accepted assurances from a bungling consultant gynaecologist that he had learnt from his mistakes has been struck off the UK medical register.

A panel of the Medical Practitioners Tribunal Service found that Robert Pitcher should have ordered a full investigation and considered restricting Rob Jones’s practice after a damning report by three independent consultants concluded that Jones had “poor clinical judgment and poor surgical technique.”

The case is the first in which a doctor has been erased from the UK register for misconduct in a managerial rather than a clinical capacity. The only other such case to be launched by the General Medical Council, against four doctors who held management positions at Mid Staffordshire NHS Foundation Trust, was dropped in 2013 before reaching a hearing.1

Pitcher was one of …
Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function
Authors: Tobias Breidthardt, Zoraida Moreno Weidmann, Raphael Twerenbold, Claudine Gantenbein, Fabio Stallone, Katharina Rentsch, Maria Rubini Gimenez, Nikola Kozhuharov, Zaid Sabti, Dominik Breitenbücher, Karin Wildi, Christian Puelacher, Ursina Honegger, Max Wagener, Carmela Schumacher, Petra Hillinger, Stefan Osswald, Christian Mueller
Journal: European Journal of Heart Failure (2016)
GW26-e2187 Association between Genetic Variation in NFKB1 and NFKBIA and Susceptibility to Coronary Artery Disease in a Chinese Han Population
Authors: Hongmei Lai, Qingjie Chen, Yining Yang, Xiaomei Li, Rui Xu, Hui Zhai, Fen Liu, Bangdang Chen, Yitong Ma
Journal: Journal of the American College of Cardiology (2015)
Abstract IA04: Stromal regulation of pancreatic cancer epigenome and metabolome
Authors: Mara H. Sherman, Ronald Evans
Journal: Cancer Research (2016)

Abstract A hallmark of pancreatic ductal adenocarcinoma (PDAC) is the dramatic accumulation of stromal components implicated in tumor growth, metastasis, and resistance to therapy. This creates a living chimera in which stroma-derived growth factors, matrix proteins and inflammatory cytokines are thought to nurture the nascent tumor. This study reveals that the stromal secretome exerts rapid epigenomic changes in the cancer cells that effectively marshals up metabolic and genomic networks needed to power cell growth. To tackle the complexity of the tumor microenvironment (TME), we devised a three-dimensional culture system to dissect the adaptive impact of the stromal secretome on the cancer cell. This integrative approach identified the rapid mobilization of more than a dozen gene networks (cell cycle, steroid biosynthesis, metabolic pathways, DNA replication, etc.), as well as a commensurate adaptive metabolome. A major unanswered question relates to the sequence of events that result in the formation and ultimate function of these networks, in part generated by rapid changes in acetylation of histone H3 at lysines 9 and 27 (H3K9ac and H3K27ac). Our work suggests the existence of a molecular and-gate such that tumor activation is the consequence of mutant Ras and the tumor micro-environment. To mediate this molecular hand-shake, we find that BRD2 acts in the epithelial compartment to transduce stromal cues at the genomic level. Based on the above, and consistent with recent Mazur PK et al Nat Med (2015), we show the BET bromodomain inhibitor JQ1 targets a key synergy point and reduces pancreatic tumor growth in vivo. Collectively, this work describes a novel connection between the stromal response and a driver oncogene and may offer new insights into the role of the TME in the treatment of ras-driven tumor. Citation Format: Mara H. Sherman, Ronald Evans. Stromal regulation of pancreatic cancer epigenome and metabolome. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA04.
Electrochemically triggered release of acetylcholine from scCO2 impregnated conductive polymer films evokes intracellular Ca2+ signaling in neurotypic SH-SY5Y cells
Authors: Susanne Löffler, Silke Seyock, Rolf Nybom, Gunilla B. Jacobson, Agneta Richter-Dahlfors
Journal: Journal of Controlled Release (2016)
Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
Authors: Joel W. Neal, Suzanne Eleanor Dahlberg, Heather A. Wakelee, Seena C. Aisner, Michaela Bowden, David Paul Carbone, Suresh S. Ramalingam
Journal: Journal of Clinical Oncology (2015)

8003 Background: Cabozantinib (C) is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2 & RET. MET is involved in tumor differentiation & VEGFR2 is a mediator of angiogenesis. Erlotinib (E) is FDA approved for the treatment of NSCLC. Methods: The primary objective of this randomized phase II study was to compare progression-free survival (PFS) of patients (pts) treated with E vs. C, & E vs E+C; each comparison had 91% power to detect a PFS hazard ratio (HR) of 0.5 with a 1-sided 0.10-level test stratified on prior number of therapies & ECOG PS. Secondary objectives included overall survival (OS), RECIST 1.1 response & CTCAE v4 toxicity. Pts were selected with previously treated (1-2 regimens) metastatic non-squamous EGFR wt NSCLC. Submission of archival tissue for central MET IHC testing was required. Oral daily dosing was: E-150 mg; C-60 mg; E+C-150 mg E, 40 mg C. Imaging was performed every 8 weeks. Pts optionally crossed over to E+C following progression on E or C. Results: One hundred and twenty-five pts were enrolled, of which 115 were eligible and treated (E, n = 39; C, n = 39; E+C, n = 37). Pt characteristics were balanced between arms except for lower rate of brain mets history on E (p = 0.02). Median follow up is 8.5 m. Compared with E (median 1.9 m), PFS was significantly improved on C (3.9 m, HR 0.33, p = 0.0002, 80% CI 0.22-0.49) and E+C (4.1 m, HR 0.31, p = 0.0002, 80% CI 0.21-0.46). Similarly, compared with E (median 4.0 m), OS was significantly improved on C (HR 0.52, p = 0.02) and E+C arm HR 0.50, p = 0.02). Grade 3-4 treatment-related hypertension & mucositis were higher on C and grade 3-4 diarrhea was higher on E+C. Overall worst grade toxicities were also significantly higher on C and E+C. MET IHC results were available on 88 patients from the primary analysis & 85% were positive (1-3+ membrane or cytoplasm staining with MET4 antibody). There was no correlation between MET status and PFS. Conclusions: C & C+E significantly improved PFS over E alone in pts with EGFR wt NSCLC. Cabozantinib-based regimens are promising for further investigation in this patient population. Funded by ECOG-ACRIN and NCI Contract No. HHSN261200800001E. Clinical trial information: NCT01708954.
GW26-e0677 Predictive Value of Serum uric acid on Left Atrial Spontaneous Echo Contrast in Non-Valvular Atrial Fibrillation Patients
Authors: Weidong Lin, Fangzhou Liu, Yumei Xue, Xianhong Fang, Xianzhang Zhan, Hongtao Liao, Shulin Wu
Journal: Journal of the American College of Cardiology (2015)
Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant.
Authors: Christy Stotler, Lisa Rybicki, Matt Kalaycio, Robert Dean, Edward A. Copelan, Ronald Sobecks, Brad Pohlman, Steven Andresen, John Sweetenham, Kelly Cherni, Josephine Chan, Brian J. Bolwell
Journal: Blood (2008)
Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN)
Authors: L. J. Wirth, R. I. Haddad, T. J. Wieczorek, J. L. Faucher, J. R. Clark, C. M. Norris, M. R. Posner
Journal: Journal of Clinical Oncology (2004)

5540 Background: Treatment options for incurable metastatic and/or locally recurrent SCCHN are limited. Platinum-based therapy yields response rates of approximately 30%, and median survival of 6–7 months. Epidermal growth factor receptor (EGFR) and Cyclooxygenase-2 (COX-2) are both overexpressed and thought to contribute to the malignant phenotype in SCCHN. The EGFR inhibitor, gefitinib, has a single-agent response rate of 11% in this population. Preclinical and pharmacodynamic data suggest that the addition of a COX-2 inhibitor may enhance the antitumor effect of gefitinib. Methods: A phase I trial was designed to determine the maximum tolerated doses (MTD) of gefitinib and celecoxib (GC) in patients with incurable SCCHN. Secondary objectives were to describe toxicities of this combination and to study biomarkers of activity, including Ki-67, CD31, activation of EGFR, ERK1/2, and Akt, and serum IL-8 and EGFR. Response will also be determined. MTD was defined as one dose level below which dose-limiting toxicities (DLTs) occurred in 2 or more of 6 patients, or the highest dose level tested. Eligible patients had measurable metastatic and/or locally recurrent SCCHN, at least 1 prior chemotherapy, performance status 2 or better, and adequate end-organ function. Results: Thus far, 12 patients have enrolled. Dose escalation and toxicities are outlined in Table 1. The most common toxicities were rash (predominately acneiform), diarrhea and hand-foot syndrome (HFS). To date, no DLTs have occurred. Three of nine evaluable patients achieved a partial response. Additional transient responses were observed. Biomarker analysis is pending. Conclusions: Overall, GC is very well-tolerated in patients with incurable SCCHN. Preliminary data suggest that celecoxib enhances gefitinib activity. A phase II study is warranted. No significant financial relationships to disclose.
Vital Signs: Dental Sealant Use and Untreated Tooth Decay Among U.S. School-Aged Children
Authors: Susan O. Griffin, Liang Wei, Barbara F. Gooch, Katherine Weno, Lorena Espinoza
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Tooth decay is one of the greatest unmet treatment needs among children. Pain and suffering associated with untreated dental disease can lead to problems with eating, speaking, and learning. School-based dental sealant programs (SBSP) deliver a highly effective intervention to prevent tooth decay in children who might not receive regular dental care. SBSPs benefits exceed their costs when they target children at high risk for tooth decay.CDC used data from the National Health and Nutrition Examination Survey (NHANES) 2011-2014 to estimate current prevalences of sealant use and untreated tooth decay among low-income (≤185% of federal poverty level) and higher-income children aged 6-11 years and compared these estimates with 1999-2004 NHANES data. The mean number of decayed and filled first molars (DFFM) was estimated for children with and without sealants. Averted tooth decay resulting from increasing sealant use prevalence was also estimated. All reported differences are significant at p<0.05.From 1999-2004 to 2011-2014, among low- and higher-income children, sealant use prevalence increased by 16.2 and 8.8 percentage points to 38.7% and 47.8%, respectively. Among low-income children aged 7-11 years, the mean DFFM was almost three times higher among children without sealants (0.82) than among children with sealants. Approximately 6.5 million low-income children could potentially benefit from the delivery of sealants through SBSP.The prevalence of dental sealant use has increased; however, most children have not received sealants. Increasing sealant use prevalence could substantially reduce untreated decay, associated problems, and dental treatment costs.
High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry
Authors: Emanuela Messa, Daniela Gioia, Andrea Evangelista, Bernardino Allione, Emanuele Angelucci, Enrico Balleari, Marco Calabrese, Massimo Catarini, Riccardo Centurioni, Paolo Danise, Liset Del Corso, Elisa Masiera, Pellegrino Musto, Fabrizio Pane, Antonella Poloni, Alessandro Sanna, Rodolfo Tassara, Gianni Ciccone, Alessandro Levis, Giuseppe Saglio, Valeria Santini
Journal: Blood (2012)
New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics
Authors: Julie Schanz, Marilyn L. Slovak, Kazuma Ohyashiki, Francesc Solé, Maria del Mar Mallo, Christian Steidl, Michael Pfeilstoecker, Thomas Noesslinger, Barbara Hildebrandt, Michael Luebbert, Mette K Andersen, Aristoteles Giagounidis, Peter Valent, Christa Fonatsch, Ulrich Germing, Detlef Haase
Journal: Blood (2008)
Management of an Unprovoked First Seizure in Adults
Authors: James X. Tao, Andrew M. Davis
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study
Authors: Jack J Olney, Paula Braitstein, Jeffrey W Eaton, Edwin Sang, Monicah Nyambura, Sylvester Kimaiyo, Ellen McRobie, Joseph W Hogan, Timothy B Hallett
Journal: The Lancet HIV (2016)

With expanded access to antiretroviral therapy (ART) in sub-Saharan Africa, HIV mortality has decreased, yet life-years are still lost to AIDS. Strengthening of treatment programmes is a priority. We examined the state of an HIV care programme in Kenya and assessed interventions to improve the impact of ART programmes on population health.
Abstract C40: Pancreatic cancer and stroma cell cross-talk affects cell proliferation in a 3D spheroid co-culture model
Authors: Jessica K. Norberg, Salvatore Nania, Rainer L. Heuchel, Matthias J. Löhr
Journal: Cancer Research (2016)

Abstract Aim of the study: The aim of this study was to validate a novel 3D spheroid co-culture model of pancreatic ductal adenocarcinoma (PDAC) cells and pancreatic stellate cells (PSCs), and to use said model as to investigate the effects of PDAC cell and PSC cross-talk on cell proliferation, cell death, migration and chemo-resistance. Methods: An eGFP-positive PSC line and PDAC cell lines were cultured in 3D spheroid mono- and co-cultures. Activation of the PSCs within the co-culture model was investigated by real time PCR for whole spheroids and spheroid populations sorted by fluorescence activated cell sorting (FACS). To investigate cell proliferation the cell numbers within the cultures were followed over time and the proportions of the different cell types within the co-cultures were monitored by FACS. Results: The mRNA expression of the PSC activation marker ASMA as well as the ECM proteins collagen I, laminin and lumican, the PDGFbeta receptor (PDGFRb) and the transforming growth factor beta1 (TGFb-1) downstream effector connective tissue growth factor (CTGF), were increased in PSCs within co-cultures compared to mono-cultures. PSCs were initially expanding but then diminished within 3D spheroid co-cultures together with two separate PDAC cell lines (Panc-1 and HPAF-II). Panc-1 cell numbers were seemingly unaffected by the presence of PSCs, but with higher proportions of PSCs the Panc1 cell numbers within the co-cultures initially were lagging behind but then caught up to the numbers within the mono-cultures. This growth switch was correlated with the opposite switch seen for the PSCs. The proliferation of HPAF-II cells, was on the other hand induced within the co-cultures compared to mono-cultures. Conclusions: PSCs are activated within the 3D spheroid co-cultures. Both tumor cell and PSC proliferation is influenced by co-culturing the cells in the 3D spheroid model. Different PDAC cell – PSC combinations are affected differently. We currently are investigating the effects on cell death and apoptosis, migration and chemo-resistance. Citation Format: Jessica K. Norberg, Salvatore Nania, Rainer L. Heuchel, Matthias J. Löhr. Pancreatic cancer and stroma cell cross-talk affects cell proliferation in a 3D spheroid co-culture model. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C40.
TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53
Authors: Koichi Takahashi, Hagop M. Kantarjian, Keyur Patel, Carlos E Bueso-Ramos, Tapan Kadia, Elias Jabbour, Courtney DiNardo, Naval Daver, Sherry Pierce, Andrew Futreal, Guillermo Garcia-Manero
Journal: Blood (2015)
Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus-Host Disease.
Authors: Eishi Ashihara, Kazuho Shimura, Chihiro Shimazaki, Shinsaku Matsunaga, Ruriko Tanaka, Asumi Yokota, Yoshihide Murotani, Miki Takeuchi, Eri Kawata, Yuri Kamitsuji, Junya Kuroda, Masafumi Taniwaki, Shinya Kimura, Taira Maekawa
Journal: Blood (2007)